This hypothesis has gained support from a recent trial that has reported that the CHRM4 positive allosteric modulator (PAM), emraclidine, reduces the severity of both acute psychotic and acute negative symptoms in people with schizophrenia (Krystal et al., 2022). Here, CHRM4 is linked to schizophrenia.